The Concept of Continuous Dopaminergic Stimulation: What We Should Consider when Starting Parkinson's Disease Treatment

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 213-215

  Stocchi, Fabrizio ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Continuous dopaminergic stimulation; Dopamine agonists; Early Parkinson's disease treatment; Parkinson's disease; Rasagiline; Ropinirole; Rotigotine

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; RASAGILINE;

BRAIN DEPTH STIMULATION; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFECT; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR;

DOPAMINE; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 77953548898     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000295667     Document Type: Conference Paper

References (12)

1. Olanow CW, Rascol O, Hauser R, et al: A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
2. Stocchi F: Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Int J Clin Pract 2006; 60: 215-221.
3. Bamford NS, Robinson S, Palmiter RD, Joyce JA, Moore C, Meshul CK: Dopamine modulates release from corticostriatal terminals. J Neurosci 2004; 24: 9541-9552.
4. Rodriguez M, Gonzalez J, Sabate M, Obeso J, Pereda E: Firing regulation in dopaminergic cells: effect of the partial degeneration of nigrostriatal system in surviving neurons. Eur J Neurosci 2003; 18: 53-60.
5. Olanow CW, Obeso JA, Stocchi F: Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677-687.
6. Jenner P: Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 2000; 47:S90-S99.
7. Bibbiani F, Costantini LC, Patel R, Chase TN: Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005; 192: 73-78.
8. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al: Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society European Section. I. Early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-1185. (Pubitemid 44581464)
9. Goetz CG, Poewe W, Rascol O, Sampaio C: Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-539.
10. Jankovic J, Watts RL, Martin W, Boroojerdi B: Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007; 64: 676-682. (Pubitemid 46789833)
11. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A: Early piribedil monotherapy of Parkinson's disease: a planned sevenmonth report of the REGAIN study. Mov Disord 2006; 21: 2110-2115.
12. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy Study Investigators: Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008; 24: 2883-2895.